Proteins specific for pyoverdine and pyochelin

Patent metadata

Field	Value
Publication number	US-10329334-B2
Application number	US-201715814737-A
Country	US
Kind code	B2
Filing date	Nov 16, 2017
Priority date	Feb 18, 2015
Publication date	Jun 25, 2019
Grant date	Jun 25, 2019

Abstract

The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa . The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.

First claim

The invention claimed is:

1. A nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising a human neutrophil gelatinase-associated lipocalin (hNGAL) mutein polypeptide having binding specificity for pyoverdine type I, wherein the hNGAL mutein comprises 10 or more mutations at positions 36, 40, 41, 49, 52, 54, 65, 68, 70, 72, 73, 75, 77, 79, 80, 81, 87, 96, 100, 103, 106, 125, 127, 132, 134, and 136 SEQ ID NO: 1.

2. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes an hNGAL mutein comprises ten or more of the following mutations of SEQ ID NO: 1: L36W, A40T, I41A, Q49P, Y52P, T54V, N65D, S68D, L70Q, R72P, K73E, K75E, D77I, W79S, I80T, R81I, C87S, N96G, Y100S, L103Q, Y106H, K125Y, S127T, Y132G, K134N, and T136A.

3. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes an hNGAL mutein comprises SEQ ID NO: 16.

4. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes an hNGAL mutein that has binding specificity for pyoverdine type I succinyl, pyoverdine type I succinamid, and/or pyoverdine type I a-ketoglutaryl.

5. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes an hNGAL mutein that is capable of binding pyoverdine type I complexed with iron with a KD of about 200 nM or lower.

6. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes an hNGAL mutein comprises 15 or more mutations at positions 36, 40, 41, 49, 52, 54, 65, 68, 70, 72, 73, 75, 77, 79, 80, 81, 87, 96, 100, 103, 106, 125, 127, 132, 134, and 136 of SEQ ID NO: 1.

7. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes an the hNGAL mutein comprises 20 or more mutations at positions 36, 40, 41, 49, 52, 54, 65, 68, 70, 72, 73, 75, 77, 79, 80, 81, 87, 96, 100, 103, 106, 125, 127, 132, 134, and 136 of SEQ ID NO: 1.

8. A host cell containing a nucleic acid molecule of claim 1 .

9. A nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising a human neutrophil gelatinase-associated lipocalin (hNGAL) mutein polypeptide having binding specificity for pyoverdine type I, wherein the hNGAL mutein comprises SEQ ID NO: 16.

10. The nucleic acid molecule of claim 9 , wherein the nucleic acid molecule encodes an hNGAL mutein consists of SEQ ID NO: 16.

11. A host cell containing a nucleic acid molecule of claim 9 .

12. The nucleic acid molecule of claim 9 , wherein the nucleic acid molecule encodes an hNGAL mutein that has binding specificity for pyoverdine type I succinyl, pyoverdine type I succinamid, and/or pyoverdine type I α-ketoglutaryl.

13. The nucleic acid molecule of claim 9 , wherein the nucleic acid molecule encodes an hNGAL mutein that is capable of binding pyoverdine type I complexed with iron with a KD of about 200 nM or lower.

Assignees

• Sanofi Sa

Inventors

• Corvey Carsten
• Stump Heike
• Kruip Jochen
• Calandra Bernhard
• Rey Astrid
• Karst Nathalie
• Mourez Michael
• Fraisse Laurent
• Rothe Christine
• Allersdorfer Andrea
• Wiedenmann Alexander
• Hinner Marlon
• Lunde Bradley
• Jensen Kristian
• Hülsmeyer Martin

Classifications

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K38/012

  from animals · CPC title

• A61K38/005 Primary

  Enzyme inhibitors (protease inhibitors A61K38/55) · CPC title

• C07K14/47 Primary

  from mammals · CPC title